Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Merck

Biotech Stocks Take A Tariffs Hit. But Pharmaceuticals Are Exempt — For Now.

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe.

Investors Business Daily

Analysts at Trump ally Howard Lutnick’s former firm call RFK Jr. ‘an anti-vax, conspiracy theorist with inadequate training’

RFK Jr. was reportedly behind the ouster of FDA’s top vaccine official and said last week that around 10,000 employees will be laid off at the Department of Health and Human Services.

Fortune

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. But AstraZeneca stock fell in line with pharma stocks.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Merck Stock Just Reminded Us Why ‘Buy the Dip’ Is Not That Simple

This healthcare company is down more than 30% over the past 52 weeks but still may not be a good buy for value investors.

Barchart

Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?

The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.

Investors Business Daily

Is Merck Stock Underperforming the S&P 500?

Despite Merck’s recent underperformance relative to the S&P 500 Index, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Wall Street Predict 92% Upside for This Dividend Stock: Should You Buy It Now?

While there are short-term headwinds, Merck has a bright future ahead.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Merck: 4 No-Brainer Reasons to Buy This Dip

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

MarketBeat

Apple, Coca-Cola, IBM, Berkshire Hathaway: These companies are facing a DEI shareholder showdown in 2025

A fresh crop of shareholder proposals that would have once been unremarkable are now a closely watched battlefront in the war against corporate diversity and inclusion initiatives.

Fortune

Stock Market Sideways Amid Trump Tariff, Inflation Fears; Palantir, Google, Amazon Among Key Movers: Weekly Review

The stock market was up and down with Trump tariff fears in focus. Palantir led big earnings winners. Google and Amazon were losers.

Investors Business Daily

Personalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows

Researchers, in a sense, manipulated each patient’s cancer in an attempt to prevent it from coming back.

Fortune

15 Stocks' Profit Grows Faster Than Any Of The Magnificent Seven

The Magnificent Seven stocks in the S&P 500 get lots of attention — for some good reasons. But top profit growth isn't one of them.

Investors Business Daily

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune

Stock Market Today: Earnings Speak Louder Than Tariffs

Recent market reaction to Trump administration policy announcements has been "entirely normal."

Kiplinger

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Today: Nasdaq, Small Caps Lead; Costco Among Multiple Breakouts (Live Coverage)

The Nasdaq dominated the major indexes Tuesday. Costco hit a new high and is in a buy zone.

Barchart

What Are Wall Street Analysts’ Target Price for Merck Stock?

Merck has considerably underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

Investors Business Daily

Dow Jones Falls On Trump Tariff News; Palantir Surges 27% On Earnings

The Dow Jones dropped Tuesday as China imposed tariffs on U.S. imports in response to President Trump's tariffs. Palantir surged on earnings.

Investors Business Daily

Merck Stock Plummets 9% As Gardasil Dynamics, 2025 Guidance Weigh On Shares

Investors hammered Merck stock Tuesday after the company beat fourth-quarter expectations, but delivered a light 2025 outlook.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Stock Index Futures Muted Ahead of U.S. JOLTs Report and Fed Speak, Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.01%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.08% this morning as investors awaited the latest reading on U.S. job openings, comments from Federal Reserve officials, and corporate earnings reports from heavyweight names.

Barchart

Stock Index Futures Slip on Trade War Concerns, U.S. JOLTs Report and Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.11% this morning as investors adopted a cautious stance after China retaliated to new U.S. tariffs.

Roll Call

Kennedy to divest interest from HPV vaccine lawsuits - Roll Call

President Donald Trump’s Health and Human Services nominee said he will divest his interest in lawsuits against an HPV vaccine manufacturer.

Investors Business Daily

The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings

Biotech stocks will need to brace for political "games" Wednesday as the Senate meets to potentially confirm RFK Jr. to lead HHS.

Top News

Robert F. Kennedy, Jr. Retains Financial Interest In Vaccine Litigation

Robert F. Kennedy, Jr. faces potential conflicts of interest as HHS secretary nominee due to financial ties with law firms handling litigation against drug...

Roll Call

How RFK Jr. drove mistrust of a cancer prevention vaccine - Roll Call

President-elect Donald Trump's pick to lead HHS has a long history of discounting and peddling misinformation about the HPV vaccine.

Investors Business Daily

Is Moderna Stock A Sell As RFK Jr. Reportedly Mulls A Massive Funding Pull?

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock a sell?

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.